RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Ultragenyx Pharmaceutical, maintaining a price target of $77.
September 26, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Ultragenyx Pharmaceutical, maintaining a price target of $77. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $77 price target by RBC Capital indicates a positive outlook on Ultragenyx's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100